Clinical Trial

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

Study acronym: POPSTAR II
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-09-26; most recent amendment 2025-07-08.
Status change: Not Yet Recruiting → Recruiting 2023-12-13
Trial Details
NCT Number NCT05560659
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Varian Medical Systems
Conditions Oligometastatic Prostate Cancer
Enrollment 92 participants
Start Date 2023-12-14
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-11